drugset / Trial / NCT04008511
Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
Phase 1/2
Unknown
54 enrolled
China Medical University, China
Liaoning Cancer Hospital & Institute · collabThe First People's Hospital of Jingzhou · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an interventional, randomized open-label, parallel-group, multicenter, dose escalation phase Ib/II study, to investigate the combination of Regorafenib and XELOX as 2nd line treatment in mCRC patients.
Timeline
- Start
- 2019-07
- Primary completion
- 2023-03
- Completion
- 2024-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 80 mg | Oral |
| Subject | Regorafenib | Small molecule | 120 mg | Oral |
| Subject | Regorafenib | Small molecule | 160 mg | Oral |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |